Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 4/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GRM6 | O15303 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297473 | 1.00 | MEN1 (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL31163362 | 1.00 | MEN1 (0.51) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL8242107 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL13331103 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL8242114 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL667426 | 0.87 | MEN1 (0.58) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3813140 | 0.86 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1HTTL3MBTL1 | |
| SCHEMBL3859569 | 0.83 | KMO (0.55) | MEN1KMT2AHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL666885 | 0.83 | KMO (0.55) | MEN1KMT2AHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL4833185 | 0.83 | NPC1 (0.48) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246888-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-03 | — | — | US | disclosed |
| US-20150246888-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-03 | — | — | US | disclosed |
| CN-102317269-B | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2015-06-17 | — | — | CN | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| EP-1117652-B1 | TAN-1057 DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6617332-B1 | Cyclic amidinourea derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| US-6576637-B1 | Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, | MERCK PATENT GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
| CN-1324348-A | TAN-1057 derivatives | BAYER AG (DE) | 2001-11-28 | — | — | CN | disclosed |
| EP-1117652-A1 | TAN-1057 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000012484-A1 | TAN-1057 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-09 | — | — | WO | disclosed |
| US-5378838-A | FOR USE IN HUMANS | MERCK & CO., INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994015924-A1 | CHOLECYSTOKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0459730-A2 | Anti-tumour compounds | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | MEN1 1111/4885KMT2A 99/4885ALDH1A1 1168/4885 |
| US-20150246888-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | TECR, FAR1, ECI1 | MEN1 4436/4885KMT2A 4160/4885ALDH1A1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.